Stock Chart
VRTX
Type: SELL growth_1yr
Strike: $560
Premium: $55.00
Expiry: Sep 17, 2027
Target: $525
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About VRTX - Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors …
Key Statistics
More VRTX Analysis
This VRTX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track VRTX's price movements with trendlines, gamma walls, and key support/resistance levels.